Hu Y, Jo H, DeGrado WF, Wang J, et al. Brilacidin, a COVID-19 Drug Candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E and NL63 through targeting both the virus and the host cell. J Med Virol 2022 Jan 25. doi: 10.1002/jmv.27616.
PMID: 35080027